AF9 anticorps (N-Term)

N° du produit ABIN358675

Cet anticorps Lapin Polyclonal détecte spécifiquement AF9 dans WB et EIA. Il présente une réactivité envers Humain.

Aperçu rapide pour AF9 anticorps (N-Term) (ABIN358675)

Antigène: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AF9 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Détail du produit anti-AF9 anticorps

Épitope: N-Term

Specificité: This antibody recognizes Human MLLT3 (N-term).

Purification: Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

Immunogène: KLH conjugated synthetic peptide selected from the N-terminal region of Human MLLT3

Isotype: Ig Fraction

Information d'application

Indications d'application: ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Détails sur AF9

Antigène: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Autre désignation: MLLT3 / AF9

Sujet: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.Synonyms: ALL1 fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, Protein AF-9, YEATS domain-containing protein 3, YEATS3

ID gène: 4300, 9606

UniProt: P42568